Shares of NeoGenomics NEO were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share were up 75.00% year over year to ($0.01), which beat the estimate of ($0.06).
Revenue of $121,724,000 higher by 39.95% year over year, which beat the estimate of $118,160,000.
Guidance
The upcoming fiscal year's EPS expected to be between ($0.27) and ($0.23).
The upcoming fiscal year's revenue expected to be between $490,000,000 and $510,000,000.
Conference Call Details
Date: Aug 06, 2021
Time: 08:30 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1219/42174
Recent Stock Performance
Company's 52-week high was at $61.57
Company's 52-week low was at $34.18
Price action over last quarter: Up 13.43%
Company Description
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
